Compare LTC Properties Inc (LTC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Merck & Co., Inc. — how do they compare? LTC Properties Inc trades at $38.12 (market cap $2.12B), while Merck & Co., Inc. trades at $130.23 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 152.4× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.78%). Which is the better fit depends on your goals.
| LTC | MRK | |
|---|---|---|
Market Cap | $2.12B | $323.00B |
Sector | Real Estate | Health |
52-Week High | $42.81 | $131.84 |
52-Week Low | $33.98 | $77.60 |
Enterprise Value | $2.86B | $369.77B |
Dividend Yield | 5.78% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $39.85, up 1.01% today, with a bullish technical signal supported by moving averages. The REIT shows strong fundamentals with a 14.08 P/E ratio, 38.93% net income margin, and consistent dividend payments of $0.19 monthly. Recent acquisitions in seniors housing (SHOP) portfolio total $285 million year-to-date, driving revenue growth from $210M in 2024 to $263M in 2025. However, earnings misses in two of the last three quarters and rising debt-to-asset ratio to 42.64% warrant caution.
Outlook remains positive due to demographic tailwinds in senior housing and aggressive SHOP expansion, but investors face risks from execution challenges in acquisitions and interest rate sensitivity. Analyst consensus is mixed with 27% buy ratings versus 59% hold, suggesting cautious optimism amid transition phase.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
